Type I interferon signature in the initiation of the immune response in vitiligo

Pigment Cell and Melanoma Research

Volumn 27, Issue 3, 2014, Pages 398-407

  Bertolotti, Antoine ^a   Boniface, Katia ^b   Vergier, Beatrice ^c   Mossalayi, Djavad ^b   Taieb, Alain ^a,b   Ezzedine, Khaled ^a,b   Seneschal, Julien ^a,b  

^a HÔPITAL PELLEGRIN   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Innate immunity; Interferon alpha; Plasmacytoid dendritic cell

Indexed keywords

ALPHA INTERFERON; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; CXCL9 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LYMPHOCYTIC INFILTRATION; MALE; MELANOCYTE; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; VITILIGO; ADOLESCENT; AUTOIMMUNE DISEASE; BIOSYNTHESIS; COMPLICATION; DENDRITIC CELL; DISEASE COURSE; GENETICS; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; NEVUS, HALO; PATHOLOGY; PHYSIOLOGY; SKIN; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; CHEMOKINE CXCL9; CHEMOTAXIS, LEUKOCYTE; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON-ALPHA; MALE; MIDDLE AGED; MYXOVIRUS RESISTANCE PROTEINS; NEVUS, HALO; RECEPTORS, CXCR3; SKIN; T-LYMPHOCYTE SUBSETS; TRANSCRIPTOME; VITILIGO; YOUNG ADULT;

EID: 84898871580     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12219     Document Type: Article

References (50)

1. Alkhateeb, A., Fain, P.R., Thody, A., Bennett, D.C., and Spritz, R.A. (2003). Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 16, 208-214.
2. Anbar, T.S., Abdel-Rahman, A.T., and Ahmad, H.M. (2008). Vitiligo occurring at site of interferon-alpha 2b injection in a patient with chronic viral hepatitis C: a case report. Clin. Exp. Dermatol. 33, 503.
3. Avraamides, G., Ng, C.Y., David, R., Gu, Y., Fazekasova, H., Mirenda, V., Foster, G.R., Runkel, L., Lombardi, G., and Marelli-Berg, F.M. (2007). IFN-alpha2 induces leucocyte integrin redistribution, increased adhesion, and migration. J. Interferon Cytokine Res. 27, 291-303.
4. Benzekri, L., Gauthier, Y., Hamada, S., and Hassam, B. (2013). Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. Br. J. Dermatol. 168, 265-271.
5. Boissy, R.E., and Manga, P. (2004). On the etiology of contact/occupational vitiligo. Pigment Cell Res. 17, 208-214.
6. Conrad, C., Meller, S., and Gilliet, M. (2009). Plasmacytoid dendritic cells in the skin: to sense or not to sense nucleic acids. Semin. Immunol. 21, 101-109.
7. Dell'anna, M.L., and Picardo, M. (2006). A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res. 19, 406-411.
8. Dwivedi, M., Laddha, N.C., Shah, K., Shah, B.J., and Begum, R. (2013). Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo. J. Interferon Cytokine Res. 33, 646-659.
9. Ezzedine, K., Lim, H.W., Suzuki, T. et al. (2012). Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 25, E1-E13.
10. Fäh, J., Pavlovic, J., and Burg, G. (1995). Expression of MxA protein in inflammatory dermatoses. J. Histochem. Cytochem. 43, 47-52.
11. Farkas, L., Beiske, K., Lund-Johansen, F., Brandtzaeg, P., and Jahnsen, F.L. (2001). Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159, 237-243.
12. + T-cell accumulation in the skin. J. Invest. Dermatol. 132, 1869-1876.
13. Jin, Y., Mailloux, C.M., Gowan, K., Riccardi, S.L., Laberge, G., Bennett, D.C., Fain, P.R., and Spritz, R.A. (2007). NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 356, 1216-1225.
14. Jin, Y., Birlea, S.A., Fain, P.R. et al. (2010a). Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N. Engl. J. Med. 362, 1686-1697.
15. Jin, Y., Riccardi, S.L., Gowan, K., Fain, P.R., and Spritz, R.A. (2010b). Fine-mapping of vitiligo susceptibility loci on chromosomes 7 and 9 and interactions with NLRP1 (NALP1). J. Invest. Dermatol. 130, 774-783.
16. Jin, Y., Birlea, S.A., Fain, P.R. et al. (2011). Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J. Invest. Dermatol. 131, 1308-1312.
17. Kwon, H.H., and Cho, K.H. (2012). Induction of Vitiligo-like hypopigmentation after imiquimod treatment of extramammary Paget's Disease. Ann. Dermatol. 24, 482-484.
18. Lande, R., and Gilliet, M. (2010). Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann. N.Y. Acad. Sci. 1183, 89-103.
19. Le Poole, I.C., and Luiten, R.M. (2008). Autoimmune etiology of generalized vitiligo. Curr. Dir. Autoimmun. 10, 227-243.
20. Le Poole, I.C., Van Den Wijngaard, R.M., Westerhof, W., and Das, P.K. (1996). Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol. 148, 1219-1228.
21. Levandowski, C.B., Mailloux, C.M., Ferrara, T.M. et al. (2013). NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1beta processing via the NLRP1 inflammasome. Proc. Natl Acad. Sci. USA 110, 2952-2956.
22. Li, H., Ice, J.A., Lessard, C.J., and Sivils, K.L. (2013). Interferons in Sjogren's Syndrome: genes, mechanisms, and effects. Front. Immunol. 4, 290.
23. Lili, Y., Yi, W., Ji, Y., Yue, S., Weimin, S., and Ming, L. (2012). Global activation of CD8 + cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS ONE 7, e37513.
24. Liu, J.B., Li, M., Chen, H., Zhong, S.Q., Yang, S., Du, W.D., Hao, J.H., Zhang, T.S., Zhang, X.J., and Zeegers, M.P. (2007). Association of vitiligo with HLA-A2: a meta-analysis. J. Eur. Acad. Dermatol. Venereol. 21, 205-213.
25. Meller, S., Gilliet, M., and Homey, B. (2009). Chemokines in the pathogenesis of lichenoid tissue reactions. J. Invest. Dermatol. 129, 315-319.
26. Mosenson, J.A., Eby, J.M., Hernandez, C., and Le Poole, I.C. (2013a). A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp. Dermatol. 22, 566-569.
27. Mosenson, J.A., Zloza, A., Nieland, J.D. et al. (2013b). Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci. Transl. Med. 5, 174ra28.
28. Nestle, F.O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu, Y.J., and Gilliet, M. (2005). Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 202, 135-143.
29. Reizis, B., Colonna, M., Trinchieri, G., Barrat, F., and Gilliet, M. (2011). Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? Nat. Rev. 11, 558-565.
30. Sandoval-Cruz, M., Garcia-Carrasco, M., Sanchez-Porras, R., Mendoza-Pinto, C., Jimenez-Hernandez, M., Munguia-Realpozo, P., and Ruiz-Arguelles, A. (2011). Immunopathogenesis of vitiligo. Autoimmun. Rev. 10, 762-765.
31. Schallreuter, K.U., Bahadoran, P., Picardo, M. et al. (2008). Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp. Dermatol. 17, 139-4; discussion 141-60.
32. Seneschal, J., Milpied, B., Vergier, B., Lepreux, S., Schaeverbeke, T., and Taieb, A. (2009). Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br. J. Dermatol. 161, 1081-1088.
33. Sheth, V.M., Guo, Y., and Qureshi, A.A. (2013). Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology 227, 311-315.
34. Shrivastav, M., and Niewold, T.B. (2013). Nucleic acid sensors and type i interferon production in systemic lupus erythematosus. Front. Immunol. 4, 319.
35. Spritz, R.A. (2011). The genetics of vitiligo. J. Invest. Dermatol. 131, E18-E20.
36. Stefanaki, C., Nicolaidou, E., Hadjivassiliou, M., Antoniou, C., and Katsambas, A. (2006). Imiquimod-induced vitiligo in a patient with genital warts. J. Eur. Acad. Dermatol. Venereol. 20, 755-756.
37. Taieb, A. (2000). Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res. 13(Suppl. 8), 41-47.
38. Taieb, A. (2007). NALP1 and the inflammasomes: challenging our perception of vitiligo and vitiligo-related autoimmune disorders. Pigment Cell Res. 20, 260-262.
39. Taieb, A. (2012). Vitiligo as an inflammatory skin disorder: a therapeutic perspective. Pigment Cell Melanoma Res. 25, 9-13.
40. Taieb, A., and Picardo, M. (2007). The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 20, 27-35.
41. Taieb, A., and Picardo, M. (2009). Clinical practice. Vitiligo. N. Engl. J. Med. 360, 160-169.
42. Tomasini, D., Mentzel, T., Hantschke, M., Cerri, A., Paredes, B., Rutten, A., Scharer, L., and Kutzner, H. (2010). Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. J. Cutan. Pathol. 37, 1132-1139.
43. Van Geel, N.A., Mollet, I.G., De Schepper, S., Tjin, E.P., Vermaelen, K., Clark, R.A., Kupper, T.S., Luiten, R.M., and Lambert, J. (2010). First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 23, 375-384.
44. Van Geel, N., Speeckaert, R., De Wolf, J., Bracke, S., Chevolet, I., Brochez, L., and Lambert, J. (2012). Clinical significance of Koebner phenomenon in vitiligo. Br. J. Dermatol. 167, 1017-1024.
45. Wenzel, J., and Tuting, T. (2007). Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp. Dermatol. 16, 454-463.
46. Wenzel, J., and Tuting, T. (2008). An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in 'interface dermatitis'. J. Invest. Dermatol. 128, 2392-2402.
47. Wenzel, J., Bekisch, B., Uerlich, M., Haller, O., Bieber, T., and Tuting, T. (2005a). Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am. J. Clin. Pathol. 124, 37-48.
48. Wenzel, J., Uerlich, M., Haller, O., Bieber, T., and Tueting, T. (2005b). Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J. Cutan. Pathol. 32, 257-262.
49. Wenzel, J., Scheler, M., Proelss, J., Bieber, T., and Tuting, T. (2006). Type I interferon-associated cytotoxic inflammation in lichen planus. J. Cutan. Pathol. 33, 672-678.
50. Wenzel, J., Wiechert, A., Merkel, C., Bieber, T., and Tuting, T. (2007). IP10/CXCL10 - CXCR3 interaction: a potential self-recruiting mechanism for cytotoxic lymphocytes in lichen sclerosus et atrophicus. Acta Derm. Venereol. 87, 112-117.